# Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients

> clinical trial · VERIFIED · 2026-06-24

Status: RECRUITING · Sponsor: National Cancer Center, Japan · Condition: Angiosarcoma of Skin

- Company: National Cancer Center, Japan
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06673628

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.